Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Hoth Therapeutics Inc (HOTH)
Hoth Therapeutics Inc (HOTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,020
  • Shares Outstanding, K 3,302
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,370 K
  • 60-Month Beta 0.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.50
Trade HOTH with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +416,350.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5000 +1.35%
on 09/29/23
3.3700 -54.89%
on 09/13/23
-0.6289 (-29.26%)
since 08/29/23
3-Month
1.5000 +1.35%
on 09/29/23
3.3700 -54.89%
on 09/13/23
-1.4797 (-49.32%)
since 06/29/23
52-Week
1.5000 +1.35%
on 09/29/23
12.5000 -87.84%
on 12/29/22
-7.6072 (-83.34%)
since 09/29/22

Most Recent Stories

More News
Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company"), a patient-focused biopharmaceutical company, today announced the closing of...

HOTH : 1.5203 (-1.92%)
Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive...

HOTH : 1.5203 (-1.92%)
Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-KIT, a new molecular entity, for...

HOTH : 1.5203 (-1.92%)
Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has submitted a request for a...

HOTH : 1.5203 (-1.92%)
Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has completed its analysis of the...

HOTH : 1.5203 (-1.92%)
Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-ALZ, a therapeutic in development...

HOTH : 1.5203 (-1.92%)
Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that the first patient has been...

HOTH : 1.5203 (-1.92%)
Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has received approval from the...

HOTH : 1.5203 (-1.92%)
Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received written...

HOTH : 1.5203 (-1.92%)
Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-ALZ a therapeutic in development...

HOTH : 1.5203 (-1.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is...

See More

Key Turning Points

3rd Resistance Point 1.7300
2nd Resistance Point 1.6800
1st Resistance Point 1.6001
Last Price 1.5203
1st Support Level 1.4702
2nd Support Level 1.4202
3rd Support Level 1.3403

See More

52-Week High 12.5000
Fibonacci 61.8% 8.2980
Fibonacci 50% 7.0000
Fibonacci 38.2% 5.7020
Last Price 1.5203
52-Week Low 1.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar